Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites

Ge HongYan; Li PeiXia; Zhang YangYang; Wang LiLi; Wei YaoLing

doi:10.3969/j.issn.1001-5256.2018.01.020

Issue 1

Jan. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(1): 97-100

PDF( 1566 KB)

Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites

DOI: 10.3969/j.issn.1001-5256.2018.01.020

Department of Gastroenterology, Affiliated Hospital of Inner Mongolia University for The Nationalities, Tongliao, Inner Mongolia 028000, China

Published Date: 2018-01-20

Abstract

Abstract

Objective To investigate the clinical effect of octreotide combined with an increased amount of fluid infusion in the treatment of intractable cirrhotic ascites, and to provide new thoughts for clinical diagnosis and treatment. Methods A total of 65 patients with intractable cirrhotic ascites who visited Affiliated Hospital of Inner Mongolia University for The Nationalities from February 2016 to May 2017 were enrolled and randomly divided into control group with 31 patients and observation group with 34 patients. The patients in the control group were given conventional treatment, and those in the observation group were given continuous pumping of octreotide 0. 6 mg once every 12 hours for 3 days, followed by intramuscular injection of octreotide 0. 2 mg once every 8 hours for 7-10 consecutive days, and an increased amount of fluid infusion, in addition to the conventional treatment. Symptomatic treatment was given based on patients' symptoms and tolerance. Vital signs, abdominal circumference, body weight, and time to ascites regression were observed during treatment, and the length of hospital stay and incidence rate of complications were analyzed. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results Compared with the control group, the observation group had significantly shorter time to ascites regression ( 6. 13 ± 1. 25 d vs 11. 61 ± 1. 34 d, t =-4. 06, P < 0. 001) and length of hospital stay ( 10. 01 ± 1. 46 d vs 16. 10 ± 1. 57 d, t =-7. 65, P < 0. 001) , as well as significantly greater average daily reductions in abdominal circumference ( 4. 01 ± 0. 75 cm vs 2. 42 ± 0. 35 cm, t = 4. 69, P < 0. 001) and body weight ( 1. 67 ± 0. 42 kg vs 0. 97 ± 0. 54 kg, t = 4. 58, P < 0. 001) . The observation group had significantly lower incidence rates of upper gastrointestinal bleeding and electrolyte disturbance than the control group ( upper gastrointestinal bleeding: 5. 88% vs 32. 26% , χ2= 7. 49, P < 0. 05; electrolyte disturbance: 8. 82% vs 38. 71% , χ2= 8. 56, P < 0. 05) . Conclusion In addition to the conventional treatment of intractable ascites, octreotide combined with an increased amount of fluid infusion can promote spontaneous dieresis, significantly reduce the amount of ascites, shorten the time to ascites regression, reduce complications, and improve patients' conditions.
- liver cirrhosis,
- ascites,
- octreotide,
- fluid therapy,
- treatment outcome

FullText(HTML)

References(15)

References

[1]ARROYO V, GINES P, GERBES AL, et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J].Hepatology, 1996, 23 (1) :164-176.

[2]CHEN Y, ZHOU L.Research advances in treatment of cirrhotic ascites[J].J Clin Hepatol, 2016, 32 (6) :1069-1074. (in Chinese) 陈煜, 周莉.肝硬化腹水治疗的新进展[J].临床肝胆病杂志, 2016, 32 (6) :1069-1074.

[3]SANGIOVANNI A, PRATI GM, FASANI P, et al.The natural history of compensated cirrhosis due to hepatitis C virus:a 17-year cohort study of 214 patients[J].Hepatology, 2006, 43 (6) :1303-1310.

[4]GE JB, XU YJ.Internal Medicine[M].8th ed.Beijing:People's Medical Publishing House, 2013:419-428. (in Chinese) 葛均波, 徐永健.内科学[M].8版.北京:人民卫生出版社, 2013:419-428.

[5]LIN PC, LIN YK, LI YB, et al.Advances in the treatment of cirrhotic ascites[J].Mod J Integr Tradit Chin West Med, 2014, 23 (29) :3299-3301. (in Chinese) 林培淳, 林勇凯, 李艺滨, 等.肝硬化腹水治疗进展[J].现代中西医结合杂志, 2014, 23 (29) :3299-3301.

[6]OCHS A, ROSSLE M, HAAG K, et al.The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites[J].N Engl J Med, 1995, 332 (18) :1192-1197.

[7]SINGHAL S, BAIKATI KK, JABBOUR II, et al.Management of refractory ascites[J].Am J Ther, 2012, 19 (2) :121-132.

[8]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[9]LIU HH, LUO SQ, FU JL, et al.Advances in the treatment of intractable cirrhotic ascites[J].J Pract Hepatol, 2011, 14 (4) :317-320. (in Chinese) 刘红虹, 罗生强, 福军亮, 等.肝硬化顽固性腹水的治疗新进展[J].实用肝脏病杂志, 2011, 14 (4) :317-320.

[10]SCHRIER RW.Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy[J].N Engl J Med, 1988, 319 (17) :1127-1134.

[11]FORTUNE B, CARDENAS A.Ascites, refractory ascites and hyponatremia in cirrhosis[J].Gastroenterol Rep (Oxf) , 2017, 5 (2) :104-112.

[12]ZHANG JL, LIU JL, LI YG, et al.The treatment discussion of refractory ascites in the cirrhosis of the liver[J].J World Latest Med Inf, 2016, 16 (100) :52-53, 56. (in Chinese) 张俊立, 刘静丽, 李艳歌, 等.肝硬化难治性腹水的治疗探讨[J].世界最新医学信息文摘, 2016, 16 (100) :52-53, 56.

[13]GUO LX.Clinical treatment in patients with liver cirrhosis refractory ascites[J].Chin Community Doct, 2016, 32 (35) :56, 58. (in Chinese) 郭丽仙.肝硬化难治性腹水的临床治疗观察[J].中国社区医师, 2016, 32 (35) :56, 58.

[14]ZHANG GQ.An analysis of clinical therapies for cirrhotic ascites[J].Chin J Mod Drug Appl, 2017, 11 (3) :133-135. (in Chinese) 张桂芹.肝硬化腹水临床的治疗方法分析[J].中国现代药物应用, 2017, 11 (3) :133-135.

[15]ZHU Q, JIANG XH, YI F, et al.The effects of octreotide on portal hemodynamics in patients with liver cirrhosis[J].Chin J Intern Med, 2004, 43 (1) :16-18. (in Chinese) 诸琦, 江晓华, 乙芳, 等.奥曲肽对肝硬化门脉血流动力学的影响[J].中华内科杂志, 2004, 43 (1) :16-18.

Relative Articles

[1]	Xin DAI, Hanlin LIU, Long CHENG, Zhulin LUO, Tao WANG. Association of programmed death-1 and programmed death-ligand 1 with the prognosis and clinical features of patients with hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2022.07.022
[2]	Pan LIU, Liang HAO, Yu CHENG, Beibei YANG, Yong WEI, Zhenhong XIA, Shoujun YU. Advances in the application of ultrasound in the diagnosis and treatment of acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2873-2876. doi: 10.3969/j.issn.1001-5256.2022.12.037
[3]	Xiangliu OUYANG, Yunxia HAN, Lichun ZHENG, Yingchun ZHAO, Xinyu SHEN, Wenjun ZHANG, Yanbin WANG. Ultrasound findings and contrast-enhanced ultrasound findings of mass-type autoimmune pancreatitis versus pancreatic ductal adenocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1351-1355. doi: 10.3969/j.issn.1001-5256.2022.06.025
[4]	Quan ZHOU, Lihui YANG, Fangqing JIANG. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1836-1840. doi: 10.3969/j.issn.1001-5256.2021.08.018
[5]	Minjun LI, Zhujian DENG, Haotian LIU, Yuxian TENG, Rongrui HUO, Xiumei LIANG, Bangde XIANG, Lequn LI, Jianhong ZHONG. Clinical effect of re-hepatic resection versus radiofrequency ablation in treatment of recurrent hepatocellular carcinoma in Asia: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1103-1109. doi: 10.3969/j.issn.1001-5256.2021.05.025
[6]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[7]	Ying LIU, Benjian GAO, Xiaoli YANG, Cheng FANG, Song SU, Bo LI. Effect of hemihepatic vascular exclusion versus total hepatic vascular exclusion in hepatectomy for primary liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(1): 73-78. doi: 10.3969/j.issn.1001-5256.2021.01.015
[8]	Shun ZHU, Zhiguo LI, Shuo LI, Xu CAO, Xiaobin LI, Xiaoke LI, Yongan YE. Effect of aspirin on the incidence rate of liver cancer in patients with viral hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1097-1102. doi: 10.3969/j.issn.1001-5256.2021.05.024
[9]	Sun DongXue, Yang Zhu, Long FengXi, Wei XianMan, Tang DongXin. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 363-368. doi: 10.3969/j.issn.1001-5256.2020.02.026
[10]	Qian Le, Ying Li. Selection of second-line drugs for adult autoimmune hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2015-2020. doi: 10.3969/j.issn.1001-5256.2020.09.021
[11]	Zhou ZiDong, Li RenLi, Chen Kai, Zhang WenCheng, Xia ShiHai. Clinical effect of epidermal growth factor receptor-targeted agents in treatment of advanced pancreatic cancer:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1097-1103. doi: 10.3969/j.issn.1001-5256.2020.05.029
[12]	Zi Li, Chen Kai, Liu GuangLin, Li RenLi, Xu Wei. Clinical effect of gemcitabine combined with high-intensity focused ultrasound in treatment of advanced pancreatic cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(1): 153-157. doi: 10.3969/j.issn.1001-5256.2020.01.034
[13]	Li Dong, Luo TianYang, Ran YaWei. Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2214-2219. doi: 10.3969/j.issn.1001-5256.2019.10.017
[14]	Wang YiBin, Liao JinTang, Xie LuLu, Qi WenJun, Chen LuYang, Li YueYi. Predictive value of preoperative ultrasound examination for factors associated with early postoperative recurrence of hepatocellular carcinoma after surgical resection [J]. Journal of Clinical Hepatology, 2015, 31(12): 2061-2065. doi: 10.3969/j.issn.1001-5256.2015.12.018
[15]	Liu LingFeng, Lu HaiYing, Yu YanYan, Wu ChiHong, Tian XiuLan. A comparative study of FibroScan and B ultrasound in diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(10): 1045-1049. doi: 10.3969/j.issn.1001-5256.2014.10.018
[16]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of pancreatic cancer (2014)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1240-1245. doi: 10.3969/j.issn.1001-5256.2014.12.003
[17]	Li ChunSheng, Ni CanRong. Expression of S100A4 and E-cadherin in pancreatic carcinoma and their relationship study[J]. Journal of Clinical Hepatology, 2006, 22(3): 207-208.
[18]	Ren Ben, Song JiangBo, Zhang FenQin, Si HongXia, Gao XuanXia. Stereotactic radiotherapy in 206 patients with pancreatic carcinoma[J]. Journal of Clinical Hepatology, 2006, 22(1): 52-53.
[20]	Yuan ZhangJi, Yang Lei, Yao Cheng, Wang GuanJun. Observation of high intensity focused ultrasound treating 40 cases of cancer of pancreas[J]. Journal of Clinical Hepatology, 2003, 19(3): 145-146.

Supplements(0)

Cited By

Cited by

Periodical cited type(37)

1.	李容容，苟悦，刘宁宁，陈日润，孙鑫，刘成海. 基于临床数据挖掘的中药对抗肿瘤药物相关肝损伤的影响及用药规律探讨. 时珍国医国药. 2024(01): 243-247 .
2.	张倩茹，卢颖，张婉婷，杨艳. 某院急性白血病患者药源性肝损伤临床治疗的回顾性分析. 遵义医科大学学报. 2024(04): 401-407 .
3.	中华医学会，中华医学会杂志社，中华医学会肝病分会药物性肝病学组，中华医学会全科医学分会，中华医学会《中华全科医师杂志》编辑委员会，中国医药生物技术协会药物性肝损伤防治技术专业委员会，中国初级卫生保健基金会药物肝脏安全性专业委员会，中国药物性肝损伤基层诊疗与管理指南制定专家组. 中国药物性肝损伤基层诊疗与管理指南(2024年). 中华全科医师杂志. 2024(08): 813-830 .
4.	郑晖，孙蓉. 药物联合应用对中草药相关肝损伤的影响. 临床肝胆病杂志. 2024(08): 1519-1524 . 本站查看
5.	李容容，李盟，苟悦，罗琼，吕桦，孙鑫，刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析. 中国药物警戒. 2023(05): 505-510 .
6.	中国医药生物技术协会药物性肝损伤防治技术专业委员会，中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志. 2023(04): 355-384 .
7.	程诗思，杨成明，曾安津. 荆州地区结核病专科医院抗结核药物不良反应分析. 临床合理用药. 2023(22): 147-150 .
8.	江程，李春晓，杨玉晴，郭静. 热毒宁注射液上市后临床安全性文献研究. 中国药事. 2023(11): 1252-1265 .
9.	王双双，熊清芳，胡一帆，陈妙洋，杨永峰. 药物性肝损伤的临床与病理特点分析. 肝脏. 2023(11): 1280-1284 .
10.	孟尧，张萌萌，郭甜甜，赵新颜. 《中国药物性肝损伤诊治指南（2023年版）》更新要点解读. 中国肝脏病杂志(电子版). 2023(04): 1-5 .
11.	马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2023(07): 397-431 .
12.	孙晓楠，吕萌，程国亭. 药物性肝损伤139例回顾性分析. 中南医学科学杂志. 2022(03): 391-394 .
13.	李娜. 肺癌患者化疗后药物性肝损伤的临床特点. 中国医药指南. 2022(16): 22-25 .
14.	劳明珠. 异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤临床效果和安全性. 临床合理用药杂志. 2022(17): 84-87 .
15.	马万龙，焦运，张旭，丁向春，张平，欧阳花，王梦甜，张乐，徐灵博，杨安宁，姜怡邓. 血清IL-6在人工肝治疗药物性肝损伤预后评估中的价值. 宁夏医科大学学报. 2022(06): 622-629 .
16.	沈婷婷，李光耀，罗琼，李盟，孙鑫，陶艳艳，周祖山，刘成海. 类风湿性关节炎患者应用雷公藤制剂及合并用药所致药物性肝损伤的临床特征分析. 临床肝胆病杂志. 2022(09): 2067-2072 . 本站查看
17.	马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2022(06): 341-375 .
18.	汪涛，王学伟，蒋元烨，曹勤，季光. 162例药物性肝损伤患者分析. 肝脏. 2021(03): 243-246 .
19.	王艳，王昱，王岚，田秋菊，杨瑞园，李柯鑫，刘立伟，王晓明，王宇，欧晓娟，贾继东，赵新颜. 中草药与西药致药物性肝损伤的临床特征及其预后的对比研究. 肝脏. 2021(04): 364-369 .
20.	杨焕芝，李兴德，陈学平，张仲安，钱彦华，蒋潇，徐艳琼，宋沧桑. 93例药物性肝损伤患者临床特征分析. 中国药业. 2021(15): 122-125 .
21.	何婷婷，王丽苹，任璐彤，崔延飞，柏兆方，郭玉明，宫嫚，王睿林. 中西药肝损伤临床及病理特征分析. 肝脏. 2021(09): 962-967 .
22.	刘秀兰，李为，郭敏，杜金凤，刘东，李娟. 药物性肝损伤相关医疗损害案例分析. 药物流行病学杂志. 2021(11): 729-734 .
23.	陈凯霞，赵广玉，印登阳，陈宏俊，黄继勋. 三种保肝药治疗化疗引起的DILI的药物经济学评价. 中国实用医药. 2021(35): 188-191 .
24.	罗琼，朱哿瑞，顾宏图，刘坤，陈高峰，邢枫，陶艳艳，刘成海. 50例中草药与西药致药物性肝损伤患者的肝组织病理学特点比较. 临床肝胆病杂志. 2020(03): 596-601 . 本站查看
25.	蔡春梅. 妊娠早期肝功能异常60例的病因分析及干预. 中国城乡企业卫生. 2020(06): 100-102 .
26.	周力. 中西药所致药物性肝损伤临床及病理特点研究. 临床医药文献电子杂志. 2020(39): 56 .
27.	纪童童，陆海英，谭宁，于岩岩，徐小元. 急、慢性药物性肝损伤临床特征的对比分析. 临床肝胆病杂志. 2020(07): 1556-1561 . 本站查看
28.	何文昌，张克恭，赵凡惠，郭芮杉，高禄化，黄长形，王临旭. 290例药物性肝损伤患者临床特征分析. 实用肝脏病杂志. 2020(04): 540-543 .
29.	李梁，陶应敏，张学敏，谢娟，陈园. 药物性肝损伤患者外周血清HIF1α和COX-2定量检测的临床价值. 肝脏. 2020(08): 848-852 .
30.	李卉，张宏亮，杨天燕，黄振光，刘滔滔，韦芳. 我院125例抗结核药物不良反应报告分析. 中国医药导报. 2020(29): 151-154 .
31.	姜正艳，郑亮. 异甘草酸镁治疗药物性肝损伤临床疗效观察. 世界最新医学信息文摘. 2019(07): 123 .
32.	张惠娟，史祖宣，赵兰芳，高天慧，李健. 56例抗肿瘤药物致肝损伤临床特点分析. 临床肝胆病杂志. 2019(03): 574-578 . 本站查看
33.	梁栋，董晓锋，张燕，朱晓红，王建斌，刘妲妲，柳伟伟，方圆，王全楚. 98例药物性肝损伤的临床特点及诊疗体会. 肝脏. 2019(04): 389-391 .
34.	黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 .
35.	郭立杰，张海丛，叶立红，王超，杜婧，伍彦辉. 中西药所致药物性肝损伤临床及病理特点分析. 临床误诊误治. 2019(08): 28-33 .
36.	吴宇宇，袁苏榆，孙四珍，王岁晶，丁洋. 药物性肝损伤诊断治疗进展概述. 药物流行病学杂志. 2018(08): 550-555 .
37.	王建青，叶珺，郜玉峰，杨利琦. 106例药物性肝损伤患者用药回顾性调查. 中国医院药学杂志. 2018(18): 1967-1970 .

Other cited types(11)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2586) PDF downloads(406)

Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites

DOI: 10.3969/j.issn.1001-5256.2018.01.020